OCTIMET Oncology NV secures over EUR 11 million to develop its highly selective MET kinase inhibitors

OCTIMET Oncology NV (OCTIMET) has secured EUR 11.3 million in a Series A investment round, enabling the company to accelerate the development of a clinically de-risked MET kinase inhibitor, as single agent or in combination with standard of care and targeted agents for the treatment of solid cancers.

For full FlandersBio press release:

http://www.pressreleasepoint.com/octimet-oncology-nv-secures-over-eur-11-million-develop-its-highly-selective-met-kinase-inhibitors